Advertisement

Multidrug Resistance and Its Circumvention in Acute Leukemia

  • A. F. List
  • C. M. Spier
  • W. S. Dalton
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

The use of intensive chemotherapy regimens produces complete remissions in up to 90% of children with acute lymphocytic leukemia, and more than half of these patients are expected to be cured of their disease [1]. Among patients with acute myeloid leukemia (AML) and adults with acute lymphocytic leukemia, sustained complete remissions are achieved in only 20%–40% of cases [2, 3]. Remission rates in patients relapsing from a complete remission are substantially lower due to development of resistance to agents employed in primary therapy and other agents to which the patient has not been exposed. In experimental systems, resistance to multiple agents most often relates to expression of P-glycoprotein, or the multidrug resistance (MDR) phenotype. In this chapter we review the role of MDR in acute leukemia and current clinical trials at the Arizona Cancer Center aimed a-restoring chemosensitivity in these disorders.

Keywords

Acute Lymphoblastic Leukemia Acute Leukemia Acute Nonlymphocytic Leukemia Mdrl Gene Multi Drug Resistance Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gaynon PS (1990) Primary treatment of childhood acute lymphoblastic leukemia of non-T-cell lineage (including infants). Hematol Oncol Clin North Am 4: 913–936Google Scholar
  2. 2.
    Champlin R, Gale RP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69: 1551–1562PubMedGoogle Scholar
  3. 3.
    Champlin R, Gale RP (1989) Acute lymphoblastic leukemia in recent advances in biology and therapy. Blood 73: 2051–2066PubMedGoogle Scholar
  4. 4.
    Beidler JL, Riehm H (1970) Cellular resistance to actinomycin-D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30: 1174–1184Google Scholar
  5. 5.
    Beck WT (1987) The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879–2887PubMedCrossRefGoogle Scholar
  6. 6.
    Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 1137–1171CrossRefGoogle Scholar
  7. 7.
    Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316: 1388–1393PubMedCrossRefGoogle Scholar
  8. 8.
    Dalton WS, Grogan TM, Rybski JA, et al. (1989) Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73: 747–752PubMedGoogle Scholar
  9. 9.
    Callen DF, Baker E, Simmers RN, Seshardri R, Roninson IB (1987). Localization of the human multiple drug resistance gene, mdr1, to 7q21.1. Hum Genet 77: 142–144PubMedCrossRefGoogle Scholar
  10. 10.
    Gros P, Neriah YB, Croop JM, et al. (1986) Isolation in expression of a complementary DNA that confers multidrug resistance. Nature 23: 728–731CrossRefGoogle Scholar
  11. 11.
    Goldstein LJ, Galsi H, Fojo A, et al. (1989) Expression of multidrug-resistant gene in human tumors. JNNCI 81: 116–124Google Scholar
  12. 12.
    Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack DG, Fojo AT (1989) Expression of the mdrl/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74: 1388–1395PubMedGoogle Scholar
  13. 13.
    Musto E Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M (1981) High risk of early resistant relapse for leukemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77: 50–53Google Scholar
  14. 14.
    Herweijer H, Sonneveld P, Baas F, Nooter K (1990) Expression of mdrl and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. JNCI 82: 1133–1140PubMedGoogle Scholar
  15. 15.
    Berry JM, Brophy NA, Smith SD, Bergstrom SK, et al. (1988) Increased expression of the multidrug resistance gene mdrl in human cancers. ASCO Proc 7: 51Google Scholar
  16. 16.
    Kato S, Ideguchi H, Muta K, Nishimura J, Nawata H (1990) Mechanisms involved in the development of Adriamycin resistance in human leukemias. Leuk Res 14: 567–573PubMedCrossRefGoogle Scholar
  17. 17.
    Mattem J, Efferth T, Back M, Ho AD,Volm M (1989) Detection of P-glycoprotein in human leukemias using monoclonal antibodies. Blut 58: 215–217Google Scholar
  18. 18.
    Dalton WS, Grogan TM, Meltzer PS, et al. (1989) Drug-resistance in multiple myeloma in non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424PubMedGoogle Scholar
  19. 19.
    Epstein J, Xiao H, Oba BK (1989) Pglycoprotein expression in plasma-cell myelorna is associated with resistance to VAD. Blood 74: 913–917PubMedGoogle Scholar
  20. 20.
    Miller TP, Grogan TM, Dalton WS, Spier CM, et al. (1991) P-glycoprotein expression in malignant lymphoma and ical drug resistance with chemotherapy and transcript levels as an indication of resistant high-dose verapamil. J Clin Oncol 9: 17–24PubMedGoogle Scholar
  21. 21.
    Kanamaru H, Kakehi Y,Yoshida O, Nakan Haematol ishi S, Pastan J, Gottesman MM (1989) MDR1 RNA levels in human renal cell carcinomas: correlation with grade and pre diction of reversal of doxorubicin resistance by quinidine in tumor explants. JNCI 81: 844–849Google Scholar
  22. 22.
    Bates SE, Mickley A, Chen YN, et al. (1989) Expression of drug resistance gene in human neuroblastoma cell lines: modulation by retinoie acid-induced differentiation. Mol Cell Biol 9: 4337–4344PubMedGoogle Scholar
  23. 23.
    Kuwazuru Y, Hanada S, Furukawa T, et al. (1990) Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 76: 2065–2071PubMedGoogle Scholar
  24. 24.
    Kato S, Nishimura J, Muta K,YufuY, Nawata H, Ideguchi H (1990) Overexpression of 35. P-glycoprotein in adult T-cell 336: 573Google Scholar
  25. 25.
    Redner A, Hegewisch S, Haimi J, Stinherz P, Jhanwar S, Andreeff M (1990) A study of multidrug resistance and cell kinetics in a child with nearhaploid acute lymphoblastic leukemia. Leuk Res 14: 771–778PubMedCrossRefGoogle Scholar
  26. 26.
    Kokenberg E, Sonneveld P, Deiwel R, Sizoo W, Hagenbeek A, Lowenberg B (1988) In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 2: 511–517 (1987)Google Scholar
  27. 27.
    Kokenberg E, Sonneveld P, Sizoo W, Hagenbeck A, Lowenberg B (1988) Cellular phar macokinetics of daunorubicin: relationships hepatocellular carcinomas. Proc Natl Acad ith the response to treatment in patients with acute myeloid leukemia. J Clin Oncol 6802–812Google Scholar
  28. 28.
    Paul C, Tidefelt U, Liliemark J, Peterson C (1989) Increasing the accumulation of daunorubicin in human leukemia cells by prolonging the infusion time. Leuk Res 13: 191–196PubMedCrossRefGoogle Scholar
  29. 29.
    Speth PAJ, Linssen PCM, Boezeman JBM, Wessels HMC, Haanen C (1987) cell and plasma daunomycin concentrations after bolus injection and 72-hour infusion Cancer Chemother Pharmacol 20: 311–315 (1982)Google Scholar
  30. 30.
    Ross D, Ordonez J, Cuddy D, Wooten P, Lee E, Thompson B, Schiffer C (1989) Verapamil enhancement of daunorubicin populations of blast cells from AML patients: relation to clinical outcome. ASCO Proc 8: 207Google Scholar
  31. 31.
    Maruyama Y, Murohashi I, Nara N, Aoki N (1989) Effects of verapamil on the cellular accumulation of daunorubicin in blast lymphatic leukemia. Br J Haematol 76: 226–230Google Scholar
  32. 32.
    Sato H, Preisler H, Day R,et al.(1990)mrdl transcript levels as an indication of resistant disease in acute myelogenous leukemia.Br J Haematol 75:340–345PubMedCrossRefGoogle Scholar
  33. 33.
    K,Sonneveld P,Oostrum R,Herweijer H, Hagenbeek T,Valerio D (1990) Overexpression of the mdrl gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline is associated with decteasedanthracycline accumulation that can be restored by cyclosporine. Int J Cancer 45: 263–268CrossRefGoogle Scholar
  34. 34.
    Ito Y,Tanimoto M,Kumazawa T,et al.(1989)Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells:sequential analuysis of 15 cases at initial presentation in relapse stage. Cancer 63:1534–1538PubMedCrossRefGoogle Scholar
  35. 35.
    Holmes J,Jacobs A, Carter G,Janowska Wieczpres A, Padua RA (1989) Multidrugresistance in haemapoietic cell lines,myelo-dysplastic syndromes and acute myeloblastic leukemia.Br J Haematol 72: 40–44Google Scholar
  36. 36.
    List AF, Spier CM, Cline A, Doll DC, Garewal H,Morgan R,Sandberg AA(1991)Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol(to bu published)Google Scholar
  37. 37.
    Fairchild CR, Ivy SP, Rushmore T, etal. (1987) Carcinogen-inducen MDR overex-pression is associated with xenobiotic resistance in rat premioplastic liver nodules in hepatocellular carcinomas. Proc Natl Acad Sci USA 84: 7705–7707CrossRefGoogle Scholar
  38. 38.
    Keith WN, Mee PJ, Brown R (1990) Response of male skin tumors to doxorubicin is dependent on carcinogen exposure. Cancer Res 50: 6841–6847PubMedGoogle Scholar
  39. 39.
    Fourth International Workshop on Chromosomes and Leukemia (1984) Correlation potential mutagenic/carcinogenic agents in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 11: 326–331Google Scholar
  40. 40.
    Golomb HM, Alimena G, Rowley JD, et al. (1982) Correlation of occupation and karyotype in adults with acute nonlymphocytic leukemia. Blood 60: 40–441Google Scholar
  41. 41.
    Ball ED, Lawrece D, Malnar M, Ciminelli N, Mayer R, Wurster-Hill D, Davey FR, Bloomfield CD (1990) Correlation of CD34 in multidrug resistance P-170 with FAB and cytogenetics but not progenosis in acute myeloid leukemia. Blood 76 (Suppl 1): 252AGoogle Scholar
  42. 42.
    Cumber PM, Jacobs A, Hay T, Fisher J, Whittaker JA, Tsuruo T (1990) Expression of the MDR gene (mdr1) and epitope masking in chronic lymphatic meukemia. Br J Haematol 76: 226–230PubMedCrossRefGoogle Scholar
  43. 43.
    Durie BGM, Dalton WS (1988) Reversal of drug resistance in multiple myeloma with verapamil. Br J Haematol 68: 203–206PubMedCrossRefGoogle Scholar
  44. 44.
    Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424PubMedGoogle Scholar
  45. 45.
    Meador J, Sweet P, Stupecky M, et al. (1987) Enhancement by Cyclosporin-A of daunorubicin efficacy in Ehlich ascites carcinoma and murine hepatoma 129. Cancer Res 47: 6216–6219PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. F. List
    • 1
  • C. M. Spier
    • 1
  • W. S. Dalton
    • 1
  1. 1.Section of Hematology/Oncology, Department of Internal Medicine and Department of PathologyUniversity of Arizona College of MedicineTucsonUSA

Personalised recommendations